
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. possesses a strong position in the biopharmaceutical market, particularly with its leading drug cabozantinib, which has demonstrated long-term efficacy in renal cell carcinoma (RCC) and expanded its indications in neuroendocrine tumors (NETs) following supportive trial data. Recent developments, including zanzalintinib's statistically significant improvement in overall survival in metastatic colorectal cancer (mCRC), suggest robust growth potential beyond cabozantinib. Overall, the positive trajectory of zanzalintinib, paired with ongoing successful outcomes for cabozantinib, informs a favorable outlook for Exelixis's stock performance.
Bears say
Exelixis Inc. faces a substantial revenue decline risk, with projections indicating an 80% drop in revenues by 2032 due to anticipated generic competition, exceeding market expectations of a 68% reduction. The company is exposed to various competitive risks, including market share erosion for its lead product, cabozantinib, and potential setbacks in its developmental pipeline, notably zanzalintinib. Additionally, failures or delays in obtaining regulatory approvals for their treatments could further jeopardize the company’s financial stability and share price.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares